Contact CFFC

Sep

Clinical Trial Alerts – September 2019

Cystic Fibrosis Foundation issued the following clinical trial alerts in the month of September.

September 17, 2019

Study of QBW276 in adults with CF

Status: Completed with results

Description: This study evaluated the safety and tolerability of QBW276, an inhaled drug designed to improve mucus clearance. This study also evaluated how the body processes the drug.

Age: 18 Years and Older

Mutation: No Mutation Requirement

Fev1% Predicted: 40 to 100%

Number of Visits: 6

Length of Participation: 14 days

ClinicalTrials.gov link: https://www.clinicaltrials.gov/ct2/show/NCT02566044

Study of adherence to lumacaftor/ivacaftor using a smart pill bottle device

Status: Completed with results

Description: This study evaluated the impact of a smart pill bottle device on adherence to lumacaftor/ivacaftor (Orkambi®).This study was for people with CF who were not currently being treated with lumacaftor/ivacaftor (Orkambi®) prior to enrolling in the study.

Age: 16 Years and Older

Mutation: Two Copies F508del

Fev1% Predicted: 40% or greater

Number of Visits: 7

Length of Participation: 48 weeks

ClinicalTrials.gov link: https://clinicaltrials.gov/ct2/show/NCT02823470

Study of VX-661 plus ivacaftor in people with CF who have two copies of the F508del CFTR mutation

Status: Completed with results

Description: This study evaluated the safety and effectiveness of the CFTR modulator drug VX-661 in combination with ivacaftor (Symdeko®). This study was for people with CF who have two copies of the F508del CFTR mutation.

Age: 18 Years and Older

Mutation: Two Copies F508del

Fev1% Predicted: 40 to 90%

Number of Visits: 6

Length of Participation: 60 days

ClinicalTrials.gov link: https://clinicaltrials.gov/ct2/show/NCT02508207


Comments are closed.